# BrightSpring Health Services, Inc.: financial statements, quarterly

BTSG · Nasdaq · CIK 1865782 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/btsg.md) · [Financials](/companies/btsg/financials.md) · [Filings](/companies/btsg/filings.md) · [Insiders](/companies/btsg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/btsg/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,239 d](/filings/0001193125-26-079454.md) | [2,286](/filings/0000950170-25-062263.md) | [2,438](/filings/0000950170-25-101119.md) | [2,601](/filings/0001193125-25-253631.md) | [2,747 d](/filings/0001193125-26-079454.md) | [2,878](/filings/0001193125-26-199339.md) | [3,148](/filings/0001193125-26-327014.md) | [3,334](/filings/0001865782-26-000012.md) | [3,551 d](/filings/0001193125-26-079454.md) | [3,614](/filings/0001193125-26-199339.md) | [3,873](/filings/0001193125-26-327014.md) | [4,213](/filings/0001865782-26-000012.md) |
| Cost of revenue | $m | not reported | [2,207](/filings/0000950170-24-051607.md) | [2,341](/filings/0000950170-24-089623.md) | [2,499](/filings/0000950170-24-119820.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [73.9 d](/filings/0001193125-26-079454.md) | [292](/filings/0000950170-25-062263.md) | [312](/filings/0000950170-25-101119.md) | [323](/filings/0001193125-25-253631.md) | [339 d](/filings/0001193125-26-079454.md) | [338](/filings/0001193125-26-199339.md) | [375](/filings/0001193125-26-327014.md) | [392](/filings/0001865782-26-000012.md) | [413 d](/filings/0001193125-26-079454.md) | [482](/filings/0001193125-26-199339.md) | [493](/filings/0001193125-26-327014.md) | [519](/filings/0001865782-26-000012.md) |
| Selling, general and administrative | $m | [94.7 d](/filings/0001193125-26-079454.md) | [308](/filings/0000950170-25-062263.md) | [274](/filings/0000950170-25-101119.md) | [294](/filings/0001193125-25-253631.md) | [283 d](/filings/0001193125-26-079454.md) | [288](/filings/0001193125-26-199339.md) | [326](/filings/0001193125-26-327014.md) | [304](/filings/0001865782-26-000012.md) | [304 d](/filings/0001193125-26-079454.md) | [361](/filings/0001193125-26-199339.md) | [362](/filings/0001193125-26-327014.md) | [358](/filings/0001865782-26-000012.md) |
| Operating income | $m | [(20.8) d](/filings/0001193125-26-079454.md) | [(15.3)](/filings/0000950170-25-062263.md) | [38.7](/filings/0000950170-25-101119.md) | [29.1](/filings/0001193125-25-253631.md) | [55.5 d](/filings/0001193125-26-079454.md) | [50.7](/filings/0001193125-26-199339.md) | [48.6](/filings/0001193125-26-327014.md) | [87.8](/filings/0001865782-26-000012.md) | [108 d](/filings/0001193125-26-079454.md) | [121](/filings/0001193125-26-199339.md) | [130](/filings/0001193125-26-327014.md) | [160](/filings/0001865782-26-000012.md) |
| Interest expense | $m | [30.4 d](/filings/0001193125-26-079454.md) | [54.5](/filings/0000950170-25-062263.md) | [43.3](/filings/0000950170-25-101119.md) | [46.6](/filings/0001193125-25-253631.md) | [46.2 d](/filings/0001193125-26-079454.md) | [41.8](/filings/0001193125-26-199339.md) | [38.8](/filings/0001193125-26-327014.md) | [38.2](/filings/0001865782-26-000012.md) | [38.5 d](/filings/0001193125-26-079454.md) | [38.6](/filings/0001193125-26-199339.md) | [36.9](/filings/0001193125-26-327014.md) | [31.0](/filings/0001865782-26-000012.md) |
| Income tax | $m | [(18.5) d](/filings/0001193125-26-079454.md) | [(26.5)](/filings/0000950170-25-062263.md) | [(13.1)](/filings/0000950170-25-101119.md) | [8.2](/filings/0001193125-25-253631.md) | [5.1 d](/filings/0001193125-26-079454.md) | [(0.2)](/filings/0001193125-26-199339.md) | [1.2](/filings/0001193125-26-327014.md) | [12.1](/filings/0001865782-26-000012.md) | [20.0 d](/filings/0001193125-26-079454.md) | [8.6](/filings/0001193125-26-199339.md) | [6.9](/filings/0001193125-26-327014.md) | [28.6](/filings/0001865782-26-000012.md) |
| Net income | $m | [(6.5) d](/filings/0001193125-26-079454.md) | [(45.8)](/filings/0000950170-25-062263.md) | [19.9](/filings/0000950170-25-101119.md) | [(8.2)](/filings/0001193125-25-253631.md) | [16.0 d](/filings/0001193125-26-079454.md) | [29.5](/filings/0001193125-26-199339.md) | [28.2](/filings/0001193125-26-327014.md) | [55.8](/filings/0001865782-26-000012.md) | [77.1 d](/filings/0001193125-26-079454.md) | [149](/filings/0001193125-26-199339.md) | [84.3](/filings/0001193125-26-327014.md) | [100](/filings/0001865782-26-000012.md) |
| Diluted EPS | $ per share | not reported | [(0.26)](/filings/0000950170-25-062263.md) | [0.10](/filings/0000950170-25-101119.md) | [(0.04)](/filings/0001193125-25-253631.md) | not reported | [0.14](/filings/0001193125-26-199339.md) | [0.13](/filings/0001193125-26-327014.md) | [0.26](/filings/0001865782-26-000012.md) | not reported | [0.67](/filings/0001193125-26-199339.md) | [0.38](/filings/0001193125-26-327014.md) | [0.45](/filings/0001865782-26-000012.md) |
| Basic EPS | $ per share | not reported | [(0.26)](/filings/0000950170-25-062263.md) | [0.10](/filings/0000950170-25-101119.md) | [(0.04)](/filings/0001193125-25-253631.md) | not reported | [0.15](/filings/0001193125-26-199339.md) | [0.14](/filings/0001193125-26-327014.md) | [0.27](/filings/0001865782-26-000012.md) | not reported | [0.73](/filings/0001193125-26-199339.md) | [0.41](/filings/0001193125-26-327014.md) | [0.48](/filings/0001865782-26-000012.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.1](/filings/0000950170-25-034196.md) | [58.0](/filings/0000950170-24-051607.md) | [25.0](/filings/0000950170-24-089623.md) | [36.0](/filings/0000950170-24-119820.md) | [61.0](/filings/0001193125-26-079454.md) | [52.3](/filings/0000950170-25-062263.md) | [70.1](/filings/0000950170-25-101119.md) | [140](/filings/0001193125-25-253631.md) | [88.4](/filings/0001865782-26-000012.md) | [889](/filings/0001193125-26-199339.md) | [550](/filings/0001193125-26-327014.md) | [718](/filings/0001865782-26-000012.md) |
| Current assets | $m | [1,457](/filings/0000950170-25-034196.md) | [1,573](/filings/0000950170-24-051607.md) | [1,522](/filings/0000950170-24-089623.md) | [1,710](/filings/0000950170-24-119820.md) | [1,893](/filings/0001193125-26-079454.md) | [2,528](/filings/0000950170-25-062263.md) | [2,648](/filings/0000950170-25-101119.md) | [2,780](/filings/0001193125-25-253631.md) | [2,894](/filings/0001865782-26-000012.md) | [2,689](/filings/0001193125-26-199339.md) | [2,470](/filings/0001193125-26-327014.md) | [2,766](/filings/0001865782-26-000012.md) |
| Total assets | $m | [5,533](/filings/0000950170-25-034196.md) | [5,656](/filings/0000950170-24-051607.md) | [5,605](/filings/0000950170-24-089623.md) | [5,786](/filings/0000950170-24-119820.md) | [5,926](/filings/0001193125-26-079454.md) | [5,847](/filings/0000950170-25-062263.md) | [5,944](/filings/0000950170-25-101119.md) | [6,049](/filings/0001193125-25-253631.md) | [6,413](/filings/0001865782-26-000012.md) | [6,213](/filings/0001193125-26-199339.md) | [5,986](/filings/0001193125-26-327014.md) | [6,267](/filings/0001865782-26-000012.md) |
| Current liabilities | $m | [1,248](/filings/0000950170-25-034196.md) | [1,245](/filings/0000950170-24-051607.md) | [1,145](/filings/0000950170-24-089623.md) | [1,264](/filings/0000950170-24-119820.md) | [1,428](/filings/0001193125-26-079454.md) | [1,458](/filings/0000950170-25-062263.md) | [1,505](/filings/0000950170-25-101119.md) | [1,550](/filings/0001193125-25-253631.md) | [1,849](/filings/0001865782-26-000012.md) | [1,548](/filings/0001193125-26-199339.md) | [1,556](/filings/0001193125-26-327014.md) | [1,711](/filings/0001865782-26-000012.md) |
| Total liabilities | $m | [4,920](/filings/0000950170-25-034196.md) | [4,081](/filings/0000950170-24-051607.md) | [3,999](/filings/0000950170-24-089623.md) | [4,167](/filings/0000950170-24-119820.md) | [4,275](/filings/0001193125-26-079454.md) | [4,156](/filings/0000950170-25-062263.md) | [4,198](/filings/0000950170-25-101119.md) | [4,228](/filings/0001193125-25-253631.md) | [4,527](/filings/0001865782-26-000012.md) | [4,223](/filings/0001193125-26-199339.md) | [3,928](/filings/0001193125-26-327014.md) | [4,081](/filings/0001865782-26-000012.md) |
| Long-term debt | $m | [3,332](/filings/0000950170-25-034196.md) | [2,515](/filings/0000950170-24-051607.md) | [2,564](/filings/0000950170-24-089623.md) | [2,609](/filings/0000950170-24-119820.md) | [2,562](/filings/0001193125-26-079454.md) | [2,489](/filings/0000950170-25-062263.md) | [2,478](/filings/0000950170-25-101119.md) | [2,465](/filings/0001193125-25-253631.md) | [2,455](/filings/0001865782-26-000012.md) | [2,445](/filings/0001193125-26-199339.md) | [2,149](/filings/0001193125-26-327014.md) | [2,147](/filings/0001865782-26-000012.md) |
| Current portion of debt | $m | [32.3](/filings/0000950170-25-034196.md) | [48.7](/filings/0000950170-24-051607.md) | [48.7](/filings/0000950170-24-089623.md) | [48.9](/filings/0000950170-24-119820.md) | [48.7](/filings/0001193125-26-079454.md) | [48.7](/filings/0000950170-25-062263.md) | [50.8](/filings/0000950170-25-101119.md) | [51.9](/filings/0001193125-25-253631.md) | [52.3](/filings/0001865782-26-000012.md) | [53.0](/filings/0001193125-26-199339.md) | [41.4](/filings/0001193125-26-327014.md) | [35.3](/filings/0001865782-26-000012.md) |
| Shareholders' equity | $m | [585](/filings/0000950170-25-034196.md) | [1,567](/filings/0000950170-24-051607.md) | [1,600](/filings/0000950170-24-089623.md) | [1,615](/filings/0000950170-24-119820.md) | [1,648](/filings/0001193125-26-079454.md) | [1,687](/filings/0000950170-25-062263.md) | [1,743](/filings/0000950170-25-101119.md) | [1,819](/filings/0001193125-25-253631.md) | [1,875](/filings/0001865782-26-000012.md) | [1,979](/filings/0001193125-26-199339.md) | [2,049](/filings/0001193125-26-327014.md) | [2,177](/filings/0001865782-26-000012.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [162 d](/filings/0001193125-26-079454.md) | [(78.9)](/filings/0000950170-25-062263.md) | [(15.2) d](/filings/0000950170-25-101119.md) | [27.2 d](/filings/0001193125-25-253631.md) | [90.6 d](/filings/0001193125-26-079454.md) | [102](/filings/0001193125-26-199339.md) | [49.1 d](/filings/0001193125-26-327014.md) | [108 d](/filings/0001865782-26-000012.md) | [232 d](/filings/0001193125-26-079454.md) | [123](/filings/0001193125-26-199339.md) | [43.9 d](/filings/0001193125-26-327014.md) | [204 d](/filings/0001865782-26-000012.md) |
| Capital expenditure | $m | [16.8 d](/filings/0001193125-26-079454.md) | [21.8](/filings/0000950170-25-062263.md) | [23.7 d](/filings/0000950170-25-101119.md) | [20.0 d](/filings/0001193125-25-253631.md) | [15.3 d](/filings/0001193125-26-079454.md) | [17.6](/filings/0001193125-26-199339.md) | [24.4 d](/filings/0001193125-26-327014.md) | [15.8 d](/filings/0001865782-26-000012.md) | [37.7 d](/filings/0001193125-26-079454.md) | [21.5](/filings/0001193125-26-199339.md) | [29.0 d](/filings/0001193125-26-327014.md) | [22.1 d](/filings/0001865782-26-000012.md) |
| Share repurchases | $m | [0.3 d](/filings/0001193125-26-079454.md) | [0.3](/filings/0000950170-25-062263.md) | [0.3 d](/filings/0000950170-25-101119.md) | [0.0 d](/filings/0001193125-25-253631.md) | [0.0 d](/filings/0001193125-26-079454.md) | not reported | not reported | not reported | not reported | [60.0](/filings/0001193125-26-199339.md) | [60.0 d](/filings/0001193125-26-327014.md) | [0.0 d](/filings/0001865782-26-000012.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [118](/filings/0000950170-24-051607.md) | [126](/filings/0000950170-24-089623.md) | [118](/filings/0000950170-24-119820.md) | [176](/filings/0000950170-25-062263.md) | [209](/filings/0000950170-25-101119.md) | [198](/filings/0001193125-25-253631.md) | [215](/filings/0001193125-26-199339.md) | [216](/filings/0001193125-26-327014.md) | [218](/filings/0001865782-26-000012.md) | [221](/filings/0001193125-26-199339.md) | [220](/filings/0001193125-26-327014.md) | [220](/filings/0001865782-26-000012.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 198,984,612 at 2026-10-27, from the cover of the [10-Q filed 2026-10-30](/filings/0001865782-26-000012.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 15:25 ET. No prices; not investment advice.